{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:24:30Z","timestamp":1791854670619,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["K23DA048062"],"award-info":[{"award-number":["K23DA048062"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jsat.2021.108494","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T02:39:07Z","timestamp":1622255947000},"page":"108494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Effectiveness of medication for opioid use disorders in transition-age youth: A systematic review"],"prefix":"10.1016","volume":"132","author":[{"given":"Sara J.","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Helseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin J.","family":"Danko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan M.","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Saldanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelen P.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale W.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108494_bb0005","first-page":"10","article-title":"Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence","author":"Amato","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.jsat.2021.108494_bb0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annemergmed.2019.07.030","article-title":"Characteristics and receipt of medication treatment among young adults who experience a nonfatal opioid-related overdose","volume":"75","author":"Bagley","year":"2020","journal-title":"Annals of Emergency Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2021.108494_bb0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0740-5472(03)00022-9","article-title":"Factors that predict adolescent motivation for substance abuse treatment","volume":"24","author":"Battjes","year":"2003","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2021.108494_bb0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/ADM.0000000000000388","article-title":"Buprenorphine treatment for adolescents and young adults with opioid use disorders: A narrative review","volume":"12","author":"Borodovsky","year":"2018","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2021.108494_bb0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.15288\/jsad.2019.80.393","article-title":"Medications for maintenance treatment of opioid use disorder in adolescents: Anarrative review and assessment of clinical benefits and potential risks","volume":"80","author":"Camenga","year":"2019","journal-title":"Journal of Studies on Alcohol and Drugs"},{"key":"10.1016\/j.jsat.2021.108494_bb0035","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.jsat.2021.108494_bb0040","series-title":"CDC\u2019s response to the opioid overdose epidemic","author":"Centers for Disease Control and Prevention","year":"2019"},{"issue":"2","key":"10.1016\/j.jsat.2021.108494_bb0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/00952990.2017.1399403","article-title":"Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions","volume":"44","author":"Chang","year":"2018","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.jsat.2021.108494_bb0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13063-019-3995-y","article-title":"A call for consensus in defining efficacy in clinical trials for opioid addiction: Combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder","volume":"21","author":"Dennis","year":"2020","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.jsat.2021.108494_bb0055","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2021.108494_bb0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drugalcdep.2015.09.020","article-title":"Memantine improves buprenorphine\/naloxone treatment for opioid dependent young adults","volume":"156","author":"Gonzalez","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108494_bb0065","first-page":"1","article-title":"Cognitive-behavioral therapy and buprenorphine for opioid use disorder: A systematic review and meta-analysis of randomized controlled trials","author":"Gregory","year":"2020","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"11","key":"10.1016\/j.jsat.2021.108494_bb0070","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatrics"},{"issue":"7829","key":"10.1016\/j.jsat.2021.108494_bb0075","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Online)"},{"issue":"4","key":"10.1016\/j.jsat.2021.108494_bb0080","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/15374416.2018.1466307","article-title":"Evidence base on outpatient behavioral treatments for adolescent substance use, 2014\u20132017: outcomes, treatment delivery, and promising horizons","volume":"47","author":"Hogue","year":"2018","journal-title":"Journal of Clinical Child and Adolescent Psychology"},{"issue":"3","key":"10.1016\/j.jsat.2021.108494_bb0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0740-5472(02)00250-7","article-title":"Adolescent heroin use: A review of the descriptive and treatment literature","volume":"23","author":"Hopfer","year":"2002","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108494_bb0090","series-title":"Federal regulation of methadone treatment","author":"Institute of Medicine (US) Committee on Federal Regulation of Methadone Treatment","year":"1995"},{"key":"10.1016\/j.jsat.2021.108494_bb0095","author":"Kaiser Family Foundation"},{"key":"10.1016\/j.jsat.2021.108494_bb0100","series-title":"StatPearls","article-title":"Buprenorphine","author":"Kumar","year":"2017"},{"issue":"8","key":"10.1016\/j.jsat.2021.108494_bb0105","first-page":"82","article-title":"The use of 1-alpha-acetyl-methadol (LAAM) as compared to methadone in the maintenance and detoxification of young heroin addicts. 1973 [proceedings]","author":"Lehmann","year":"1976","journal-title":"NIDA Research Monograph"},{"issue":"2","key":"10.1016\/j.jsat.2021.108494_bb0110","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2752","article-title":"Youth and the opioid epidemic","volume":"143","author":"Levy","year":"2019","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jsat.2021.108494_bb0115","article-title":"Medication-assisted treatment of adolescents with opioid use disorders","volume":"138","author":"Levy","year":"2016","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.jsat.2021.108494_bb0120","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archpsyc.62.10.1157","article-title":"Comparison of pharmacological treatments for opioid-dependent adolescents: A randomized controlled trial","volume":"62","author":"Marsch","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1016\/j.jsat.2021.108494_bb0125","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/add.13363","article-title":"A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults","volume":"111","author":"Marsch","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108494_bb0130","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.jsat.2021.108494_bb0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Systematic Reviews"},{"key":"10.1016\/j.jsat.2021.108494_bb0140","series-title":"Suboxone and subtex approval letter","volume":"Vol. 732","author":"McCormick","year":"2002"},{"issue":"6","key":"10.1016\/j.jsat.2021.108494_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007210.pub3","article-title":"Maintenance treatments for opiate-dependent adolescents","volume":"2014","author":"Minozzi","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2021.108494_bb0150","series-title":"Adolescent substance use: America\u2019s #1 public health problem","author":"National Center on Addiction and Substance Abuse","year":"2011"},{"issue":"2","key":"10.1016\/j.jsat.2021.108494_bb0155","doi-asserted-by":"crossref","first-page":"v","DOI":"10.1590\/S0103-21002007000200001","article-title":"Systematic literature review X narrative review","volume":"20","author":"Rother","year":"2007","journal-title":"Acta Paulista de Enfermagem"},{"issue":"4","key":"10.1016\/j.jsat.2021.108494_bb0160","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0351","article-title":"Brief behavioral interventions for substance use in adolescents: A meta-analysis","volume":"146","author":"Steele","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.jsat.2021.108494_bb0165","series-title":"Interventions for Substance Use Disorders in Adolescents: A Systematic Review","article-title":"Interventions for substance use disorders in adolescents: A systematic review","author":"Steele","year":"2020"},{"key":"10.1016\/j.jsat.2021.108494_bb0170","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.jsat.2021.108494_bb0175","series-title":"Medications for opioid use disorder. Treatment improvement protocol (TIP) series 63. Publication No. PEP20-02-01-006","author":"Substance Abuse and Mental Health Services Administration","year":"2020"},{"key":"10.1016\/j.jsat.2021.108494_bb0180","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.jsat.2021.108494_bb0185","unstructured":"Wells, G., Shea, B., Robertson, J., Peterson, J., Welch, V., Losos, M., Tugwell, P. (n.d.). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Retrieved September 24, 2020, from http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"5","key":"10.1016\/j.jsat.2021.108494_bb0190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/HRP.0000000000000272","article-title":"A review of behavioral therapies in adolescents with opioid use disorder","volume":"28","author":"Welsh","year":"2020","journal-title":"Harvard Review of Psychiatry"},{"key":"10.1016\/j.jsat.2021.108494_bb0195","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.addbeh.2015.02.014","article-title":"Progression to regular heroin use: Examination of patterns, predictors, and consequences","volume":"45","author":"Woodcock","year":"2015","journal-title":"Addictive Behaviors"},{"issue":"17","key":"10.1016\/j.jsat.2021.108494_bb0200","first-page":"2003","article-title":"Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth a randomized trial","volume":"300","author":"Woody","year":"2008","journal-title":"JAMA\u202f: The Journal of the American Medical Association"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221002208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221002208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:54:19Z","timestamp":1760039659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221002208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":39,"alternative-id":["S0740547221002208"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108494","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of medication for opioid use disorders in transition-age youth: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108494"}}